Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen : Merck KGaA Reverses EUR365 Million Provision for U.S. Lawsuit

share with twitter share with LinkedIn share with facebook
09/29/2020 | 01:58pm EDT

By Kim Richters

Merck KGaA said Tuesday that is reversing a 365 million euros ($425.8 million) provision for patent dispute proceedings in the U.S.

The provision relates to a patent dispute of its subsidiary EMD Serono Inc. with Biogen Inc. about Merck's product Rebif.

Merck said its decision comes after the U.S. Court of Appeals for the Federal Circuit ruled in favor of the German pharmaceutical-and-chemical company on Monday.

Merck added that it might book a provision of up to a mid- to high-double-digit million amount and will adjust its outlook accordingly.

 

Write to Kim Richters at kim.richters@wsj.com

 


Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -3.11% 256.76 Delayed Quote.-13.37%
MERCK KGAA -0.76% 130.85 Delayed Quote.24.21%
share with twitter share with LinkedIn share with facebook
All news about BIOGEN INC.
10/22BIOGEN : Reports Q3 2020 Results
AQ
10/21BIOGEN : Management's Discussion and Analysis of Financial Condition and Results..
AQ
10/21BIOGEN : readies for U.S. launch of Alzheimer's drug ahead of FDA meeting
RE
10/21BIOGEN : Cuts Guidance Amid Competition From Generics
DJ
10/21BIOGEN : Posts Lower 4Q Profit as Pharmaceutical Revenue Declines
DJ
10/21BIOGEN INC. : Results of Operations and Financial Condition, Other Events, Finan..
AQ
10/21BIOGEN : readies for U.S. launch of Alzheimer's drug ahead of FDA meeting
RE
10/21BIOGEN : Reports Q3 2020 Results
PU
10/21BIOGEN : Reports Q3 2020 Earnings
PU
10/21BIOGEN : Q3 2020 Biogen Earnings Presentation
PU
More news
Financials (USD)
Sales 2020 13 446 M - -
Net income 2020 4 531 M - -
Net Debt 2020 2 478 M - -
P/E ratio 2020 9,16x
Yield 2020 -
Capitalization 39 557 M 39 557 M -
EV / Sales 2020 3,13x
EV / Sales 2021 3,39x
Nbr of Employees 7 400
Free-Float 86,1%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 33
Average target price 295,04 $
Last Close Price 257,06 $
Spread / Highest target 50,2%
Spread / Average Target 14,8%
Spread / Lowest Target -22,2%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & EVP-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.-10.69%40 779
CSL LIMITED7.34%95 394
WUXI BIOLOGICS (CAYMAN) INC.121.59%38 375
SAMSUNG BIOLOGICS CO.,LTD.45.50%37 233
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.186.79%34 384
ALEXION PHARMACEUTICALS, INC.12.45%26 654